COMBINED EFFECTS OF LONIDAMINE AND TAMOXIFEN IN HUMAN BREAST-CANCER CELL-LINES
- D GORNATI
- N ZAFFARONI
- L ORLANDI
- G DIFRONZO
- R SILVESTRINI
Affiliations: IST NAZL STUDIO & CURA TUMORI,DIV ONCOL SPERIMENTALE C,I-20133 MILAN,ITALY.
- Published online on: May 1, 1995 https://doi.org/10.3892/ijo.6.5.993
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The antiproliferative activity of lonidamine, alone or in combination with the antiestrogen tamoxifen, was studied on estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. Lonidamine by itself induced an appreciable cytotoxic effect on all five cell lines, with 50% inhibitory concentrations (IC50) ranging from 19.5 to 54 mu M. The combination of lonidamine and tamoxifen, simultaneously administered or in sequence, provided additive effects on the estrogen receptor-negative MCF/DX cell line and a sub-additive interaction in the estrogen receptor-positive MCF7 cells. The negative interference between the two drugs could be ascribed to the marked reduction induced by lonidamine in the expression of estrogen receptor in the MCF7 cells.